12 www.thelancet.com/neurology Vol 17 January 2018 2 Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 2017; 114: 10719–24. 3 Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–70. 4 Hauser SL, Bar-Or A, Comi G, et al. OPERA I and OPERA II clinical investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221–34. 5 Montalban X. Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–20. 6 Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017; 16: 189–99. 7 Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 2017; published online Oct 10. https://doi.org/10.1016/S01406736(17)32346-2.

中文翻译：

---

神经肌肉疾病：2017，值得铭记的一年

12 www.thelancet.com/neurology Vol 17 January 2018 2 Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z. 来自多发性硬化症患者的肠道微生物群使小鼠发生自发性自身免疫性脑脊髓炎。Proc Natl Acad Sci USA 2017；114：10719-24。3 Disanto G、Barro C、Benkert P 等。血清神经丝光：多发性硬化症神经元损伤的生物标志物。安神经元 2017 年；81: 857–70。4 Hauser SL、Bar-Or A、Comi G 等。OPERA I 和 OPERA II 临床研究人员。Ocrelizumab 与干扰素β-1a 在复发性多发性硬化症中的比较。N Engl J Med 2017；376：221-34。5 Montalban X. Hauser SL、Kappos L 等。Ocrelizumab 对比安慰剂治疗原发性进行性多发性硬化症。N Engl J Med 2017；376：209-20。6 Cadavid D、Balcer L、Galetta S 等。opicinumab 在急性视神经炎 (RENEW) 中的安全性和有效性：一项随机、安慰剂对照的 2 期试验。柳叶刀神经病 2017；16：189-99。7 Green AJ、Gelfand JM、Cree BA、Bevan C、Boscardin WJ、Mei F.富马酸克莱马斯汀作为多发性硬化症的髓鞘再生疗法 (ReBUILD)：一项随机、对照、双盲、交叉试验。柳叶刀 2017；10 月 10 日在线发布。https://doi.org/10.1016/S01406736(17)32346-2。